Elanco Animal Health

ELAN

Market cap $12.1B

Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Elanco Animal Health earns a buy rating, driven by robust product innovation, commercial execution, and a credible deleveraging plan. ELAN's 'Big 6' innovation portfolio is set to contribute ~$1.1 billion in 2026 revenue, supporting margin expansion and portfolio renewal. Credelio Quattro and Zenrelia demonstrate ELAN's ability to capture share from incumbents, with rapid adoption and strong sequential growth.

INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.

Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment, as needed USDA approval of Befrena reinforces Elanco's commitment to going beyond to deliver differentiated, high-quality products in every key therapeutic area, bolstering its leadership in canine dermatology and monoclonal antibodies (mAbs) Canine allergic and atopic dermatitis is a widespread concern amongst veterinarians, with data revealing that nearly 98% of vets say they routinely treat dogs for atopic dermatitis and that itchy dogs make up nearly 20% of their patient populationi INDIANAPOLIS, Ind., Dec. 31, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology space with the U.S. Department of Agriculture (USDA) approval of Befrena™ (tirnovetmab), a new anti-IL31 monoclonal antibody (mAb) injection targeting canine allergic and atopic dermatitis.

Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional Approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first for companion animals against New World screwworm Action follows previous Emergency Use Authorizations granted by the FDA for Credelio™ (lotilaner) and Credelio™ CAT (lotilaner) to treat New World screwworm in dogs and cats, respectively Credelio Quattro/Credelio Quattro-CA1 provides the broadest parasite coverage of its kind* - covering seven types of parasites including ticks, fleas, heartworm disease, roundworms, hookworms, tapeworms, and now New World screwworm** Published literature shows lotilaner, an active ingredient in Credelio Quattro-CA1, has a reasonable expectation of effectiveness for the treatment of infestations caused by New World screwwormi INDIANAPOLIS , Dec. 18, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm larvae (myiasis) in dogs. This is the first FDA conditional approval for a companion animal product to treat New World screwworm.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Elanco Animal Health Incorporated (NYSE: ELAN).

Here is how Elanco Animal Health Incorporated (ELAN) and Tactile Systems Technology (TCMD) have performed compared to their sector so far this year.

Elanco Animal Health (ELAN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript

On Tuesday, Elanco Animal Health Incorporated (NYSE: ELAN) used its first Investor Day in five years to signal a turning point for the company, outlining a more focused strategy aimed at sustainable growth, margin expansion, and a stronger balance sheet.